Bayer Pharmaceutical’s new anticoagulant drug Xarelto (generic name rivaroxaban) has been associated with an increased risk of severe side effects, including upper gastrointestinal bleeding (UGIB). Symptoms of gastrointestinal bleeding can include severe stomach pain and coughing up blood, among many other signs.
More than 100 cases of UGIB have been directly linked to Xarelto, which is prescribed to patients who are at a risk for blood clots. Bleeding in the upper GI tract due to Xarelto can occur several places, including the esophagus, stomach, and duodenum—resulting in death in as many as 10% of cases.
More than 1,800 adverse events have been associated with Xarelto since the drug was approved by the U.S. Food and Drug Administration in 2011. Nearly half of those events resulted in hospitalization, with at least 183 Xarelto deaths associated with the drug.